Navigation Links
Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study

- Gleevec found to dramatically reduce the risk of cancer returning after surgery for Kit-positive gastrointestinal stromal tumors (GIST)

EAST HANOVER, N.J., April 12, 2007 /PRNewswire/ -- Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.

The interim analysis showed no recurrence of cancer in approximately 97% of patients given Gleevec for a year after surgery to remove tumors, compared to approximately 83% of those who underwent surgery but received a placebo. The investigators made these results public because the study had met its primary endpoint in terms of rate of recurrence-free survival.

The study involving more than 600 patients was sponsored by the National Cancer Institute (NCI), part of the US National Institutes of Health (NIH). It was conducted at multiple cancer centers in the US and Canada, and was led by the of Surgeons Oncology Group. Novartis supplied Gleevec for use in the study, and also provided partial funding under a Cooperative Research and Development Agreement with NCI to support the clinical development of Gleevec.

Gleevec has already been confirmed as an effective therapy in its approved use for patients with advanced metastatic or unresectable (inoperable) Kit- positive GIST. In a statement issued today by the NIH, the new findings were heralded as excellent news, with major implications for patients with primary disease.

"With these new data, we see that Gleevec may help patients with early GIST," said Diane Young, MD, Head of Global Medical Affairs at Novartis Oncology. "We will now work with the investig
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:9/19/2014)... 19, 2014 Medical science liaisons (MSLs) ... key opinion leaders (KOLs) who can provide essential ... critical nature of the MSL function, the changing ... the landscape for creating and maintaining KOL and ... the oversight responsibility for the MSL function is ...
(Date:9/19/2014)... 2014 Harwood Feffer LLP ( www.hfesq.com ) ... of PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: ... breached its fiduciary duties to shareholders or violated the ... the Company disclosed: "On September 11, 2014, [PDL] was ... & Young LLP ("EY"), that it was resigning effective ...
(Date:9/19/2014)... N.C. , Sept. 19, 2014 A ... Best Practices, LLC with three issues he wanted the ... The use of external personnel (especially for secondary research) ... in the face of increased workload , Automation ... better knowledge management , How to implement and ...
Breaking Medicine Technology:Role of Medical Science Liaisons Shifting in Healthcare Industry 2Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2In Era of Competing Needs, Market Research Groups Under Pressure to Utilize Automation and External Staffing 2
... DEERFIELD, IL, June 04, 2007,/PRNewswire-FirstCall/ - Cardiome ... US, Inc. ("Astellas") today,announced results from their ... 2. The trial evaluated the efficacy and ... (iv)") for the treatment of patients who ...
... -- ZymoGenetics,Inc. today announced that interim findings were ... in B-cell chronic,lymphocytic leukemia (B-CLL) at the American ... study included intravenous,administration of higher doses than had ... atacicept was well-tolerated and biologically,active at all dose ...
Cached Medicine Technology:Cardiome And Astellas Announce Positive Results From ACT 2 Trial 2Cardiome And Astellas Announce Positive Results From ACT 2 Trial 3Cardiome And Astellas Announce Positive Results From ACT 2 Trial 4Cardiome And Astellas Announce Positive Results From ACT 2 Trial 5Cardiome And Astellas Announce Positive Results From ACT 2 Trial 6ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 2ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 3
(Date:9/20/2014)... The festival season is coming soon. The ... released luxurious cocktail dresses . A lot of sophisticated ... to launch a new promotion for its high quality clothes. ... discounted price, from 20 to 71 percent off. , ... choices. They are provided in many fashionable colors. Mary, the ...
(Date:9/20/2014)... September 20, 2014 Ticket Down ... concert tickets for her 2015 “Honeymoon Tour.” This well-known ... for added savings. , In early 2015, fans will have ... the world across North America. Twenty-one-year-old Ariana Grande will hit ... will take her to 25 cities across the United States ...
(Date:9/20/2014)... New PharmaPoint Drug Evaluation report, “Symbicort ... The asthma market saw very slow growth over ... with relatively efficacious standard therapies, such as short-acting ... long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has ... launch of seven novel targeted biologic agents and ...
(Date:9/20/2014)... York (PRWEB) September 20, 2014 ... ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries continue ... another insurer has announced plans to end coverage ... on its website last month, Harrisburg, Pennsylvania-based Capital ... November 1, 2014. The insurer said its decision ...
(Date:9/20/2014)... iFitDress.com, the popular online supplier of wedding dresses and ... new collection of cocktail gowns. This afternoon, the company ... new outfits; it intends to expand its online market ... cheap cocktail dresses in the company’s online ... extensive experience in the industry of women’s special occasion ...
Breaking Medicine News(10 mins):Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:Fashionable Cocktail Dresses Unveiled Online at iFitDress.com 2
... cut unnecessary biopsies, researchers say , WEDNESDAY, March 3 ... ways to treat and detect stubborn forms of prostate ... being presented this week at the annual Genitourinary Cancers ... of the prostate, kidney, bladder and testicles," Dr. Nicholas ...
... ... ... ... ...
... ... ... ... WASHINGTON , March 3 Michael A. Stephens , MPH, has joined the Association of ...
... commonly believed , WEDNESDAY, March 3 (HealthDay News) -- Early ... to a new study that may trigger a major change ... been believed that glaucoma -- the leading cause of blindness ... eye that damages the retina and optic nerve, so treatments ...
... ... ... ... ...
... MAYWOOD, Ill. -- A daily dose of vitamin D may ... winter, according to researchers at Loyola University Chicago Marcella Niehoff ... weather months when days are short and more time is ... problem despite the nutrient,s widely reported health benefits," said Sue ...
Cached Medicine News:Health News:New Drugs, Approaches Offer Hope Against Prostate Cancer 2Health News:New Drugs, Approaches Offer Hope Against Prostate Cancer 3Health News:New Drugs, Approaches Offer Hope Against Prostate Cancer 4Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 2Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 3Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 4Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 5Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 6Health News:Michael A. Stephens Appointed Senior Policy Director at Association of Schools of Public Health 2Health News:Michael A. Stephens Appointed Senior Policy Director at Association of Schools of Public Health 3Health News:Glaucoma Begins in Mid-Brain, Not in Eye, Research Shows 2Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 2Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 3Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 4Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 5Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 6Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 7Health News:Vitamin D lifts mood during cold weather months 2
Hartman Mosquito forceps, straight, 3.5"....
Straight 20 mm serrated jaws. Ring handle with ratchet lock and dull finish. Overall length 3.9 inches...
Curved 21 mm serrated jaws. Ring handle with ratchet lock and dull finish. Most popular size or model. Overall length 4.7 inches...
Straight 22 mm serrated jaws. Ring handle with ratchet lock and dull finish. Overall length 4.9 inches...
Medicine Products: